Giulio Pasinetti

Summary

Affiliation: Mount Sinai School of Medicine
Country: USA

Publications

  1. pmc Microglia activation in the brain as inflammatory biomarker of Alzheimer's disease neuropathology and clinical dementia
    Zhongmin Xiang
    Department of Psychiatry, The Mount Sinai School of Medicine, New York, NY, 10029 6574, USA
    Dis Markers 22:95-102. 2006
  2. pmc Vgf is a novel biomarker associated with muscle weakness in amyotrophic lateral sclerosis (ALS), with a potential role in disease pathogenesis
    Zhong Zhao
    James J Peters Veterans Affairs Medical Center, Bronx, NY 10468, USA
    Int J Med Sci 5:92-9. 2008
  3. pmc S100A7, a novel Alzheimer's disease biomarker with non-amyloidogenic alpha-secretase activity acts via selective promotion of ADAM-10
    Weiping Qin
    Department of Psychiatry, Mount Sinai School of Medicine, New York, New York, USA
    PLoS ONE 4:e4183. 2009
  4. pmc Caloric intake, dietary lifestyles, macronutrient composition, and alzheimer' disease dementia
    Giulio Maria Pasinetti
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Alzheimers Dis 2011:806293. 2011
  5. pmc Role of Hypertension in Aggravating Abeta Neuropathology of AD Type and Tau-Mediated Motor Impairment
    C Diaz-Ruiz
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY10029, USA
    Cardiovasc Psychiatry Neurol 2009:107286. 2009
  6. pmc Insulin receptor expression and activity in the brains of nondiabetic sporadic Alzheimer's disease cases
    Lap Ho
    Department of Neurology, Mount Sinai School of Medicine, 1468 Madison Avenue, New York, NY 10029, USA
    Int J Alzheimers Dis 2012:321280. 2012
  7. pmc Caprylic triglyceride as a novel therapeutic approach to effectively improve the performance and attenuate the symptoms due to the motor neuron loss in ALS disease
    Wei Zhao
    Department of Neurology, Mount Sinai School of Medicine, New York, New York, United States of America
    PLoS ONE 7:e49191. 2012
  8. pmc Unintended effects of cardiovascular drugs on the pathogenesis of Alzheimer's disease
    Jun Wang
    Department of Neurology, Mount Sinai School of Medicine, New York, New York, United States of America
    PLoS ONE 8:e65232. 2013
  9. pmc Molecular topology as novel strategy for discovery of drugs with aβ lowering and anti-aggregation dual activities for Alzheimer's disease
    Jun Wang
    Department of Neurology, Mount Sinai School of Medicine, New York, New York, United States of America Geriatric Research, Education and Clinical Center, James J Peters Veterans Affairs Medical Center, Bronx, New York New York, United States of America
    PLoS ONE 9:e92750. 2014
  10. pmc Sirtuins as therapeutic targets of ALS
    Giulio Maria Pasinetti
    Department of Neurology, Mount Sinai School of Medicine, 1468 Madison Avenue, Annenberg Building, Room 20 02, New York, NY 10029, USA
    Cell Res 23:1073-4. 2013

Collaborators

Detail Information

Publications54

  1. pmc Microglia activation in the brain as inflammatory biomarker of Alzheimer's disease neuropathology and clinical dementia
    Zhongmin Xiang
    Department of Psychiatry, The Mount Sinai School of Medicine, New York, NY, 10029 6574, USA
    Dis Markers 22:95-102. 2006
    ..These results suggest that microglia activation increases with the progression of AD, with the increase varying depending on the involved brain region...
  2. pmc Vgf is a novel biomarker associated with muscle weakness in amyotrophic lateral sclerosis (ALS), with a potential role in disease pathogenesis
    Zhong Zhao
    James J Peters Veterans Affairs Medical Center, Bronx, NY 10468, USA
    Int J Med Sci 5:92-9. 2008
    ....
  3. pmc S100A7, a novel Alzheimer's disease biomarker with non-amyloidogenic alpha-secretase activity acts via selective promotion of ADAM-10
    Weiping Qin
    Department of Psychiatry, Mount Sinai School of Medicine, New York, New York, USA
    PLoS ONE 4:e4183. 2009
    ....
  4. pmc Caloric intake, dietary lifestyles, macronutrient composition, and alzheimer' disease dementia
    Giulio Maria Pasinetti
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Int J Alzheimers Dis 2011:806293. 2011
    ..We further discuss how the consumption of certain foods or food components can help to reduce one's risk for Alzheimer's disease and may possibly be developed as a therapeutic agent...
  5. pmc Role of Hypertension in Aggravating Abeta Neuropathology of AD Type and Tau-Mediated Motor Impairment
    C Diaz-Ruiz
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY10029, USA
    Cardiovasc Psychiatry Neurol 2009:107286. 2009
    ..Our studies suggest that the management of blood pressure (BP) may alleviate AD-type Abeta neuropathology and neurological disorders associated with abnormal tau metabolism...
  6. pmc Insulin receptor expression and activity in the brains of nondiabetic sporadic Alzheimer's disease cases
    Lap Ho
    Department of Neurology, Mount Sinai School of Medicine, 1468 Madison Avenue, New York, NY 10029, USA
    Int J Alzheimers Dis 2012:321280. 2012
    ..Outcomes from our study support the development of insulin-sensitizing therapeutic strategies to stimulate downstream IR signaling in nondiabetic AD cases...
  7. pmc Caprylic triglyceride as a novel therapeutic approach to effectively improve the performance and attenuate the symptoms due to the motor neuron loss in ALS disease
    Wei Zhao
    Department of Neurology, Mount Sinai School of Medicine, New York, New York, United States of America
    PLoS ONE 7:e49191. 2012
    ..These data indicate the feasibility of using caprylic acid as an easily administered treatment with a high impact on the quality of life of ALS patients...
  8. pmc Unintended effects of cardiovascular drugs on the pathogenesis of Alzheimer's disease
    Jun Wang
    Department of Neurology, Mount Sinai School of Medicine, New York, New York, United States of America
    PLoS ONE 8:e65232. 2013
    ....
  9. pmc Molecular topology as novel strategy for discovery of drugs with aβ lowering and anti-aggregation dual activities for Alzheimer's disease
    Jun Wang
    Department of Neurology, Mount Sinai School of Medicine, New York, New York, United States of America Geriatric Research, Education and Clinical Center, James J Peters Veterans Affairs Medical Center, Bronx, New York New York, United States of America
    PLoS ONE 9:e92750. 2014
    ..Topological characterization has been shown to embody sufficient molecular information to provide strong correlation to therapeutic efficacy...
  10. pmc Sirtuins as therapeutic targets of ALS
    Giulio Maria Pasinetti
    Department of Neurology, Mount Sinai School of Medicine, 1468 Madison Avenue, Annenberg Building, Room 20 02, New York, NY 10029, USA
    Cell Res 23:1073-4. 2013
    ....
  11. doi request reprint Novel role of red wine-derived polyphenols in the prevention of Alzheimer's disease dementia and brain pathology: experimental approaches and clinical implications
    Giulio Maria Pasinetti
    Department of Neurology, Mount Sinai School of Medicine, New York, NY, USA
    Planta Med 78:1614-9. 2012
    ....
  12. pmc Identification of brain-targeted bioactive dietary quercetin-3-O-glucuronide as a novel intervention for Alzheimer's disease
    Lap Ho
    Department of Neurology, Mt Sinai School of Medicine, New York, NY 10029, USA
    FASEB J 27:769-81. 2013
    ....
  13. pmc Dietary composition modulates brain mass and solubilizable Abeta levels in a mouse model of aggressive Alzheimer's amyloid pathology
    Steve Pedrini
    Farber Institute for the Neurosciences, Jefferson Medical College, Philadelphia PA USA
    Mol Neurodegener 4:40. 2009
    ..abstract:..
  14. pmc Complement anaphylatoxin C5a neuroprotects through regulation of glutamate receptor subunit 2 in vitro and in vivo
    Piali Mukherjee
    Department of Psychiatry, Mount Sinai School of Medicine, 1 Gustav L, Levy Place, New York, NY 10029, USA
    J Neuroinflammation 5:5. 2008
    ..In this study we explored potential upstream mechanisms involved in C5a mediated neuroprotection in vivo and in vitro...
  15. pmc A ketogenic diet as a potential novel therapeutic intervention in amyotrophic lateral sclerosis
    Zhong Zhao
    Neuroinflammation Research Laboratories, Department of Psychiatry, USA
    BMC Neurosci 7:29. 2006
    ..The cause of neuronal death in amyotrophic lateral sclerosis (ALS) is uncertain but mitochondrial dysfunction may play an important role. Ketones promote mitochondrial energy production and membrane stabilization...
  16. pmc Metabolic syndrome and the role of dietary lifestyles in Alzheimer's disease
    Giulio Maria Pasinetti
    Center of Excellence for Research in Complementary and Alternative Medicine in Alzheimer s Disease, Department of Psychiatry, The Mount Sinai School of Medicine, New York, New York, USA
    J Neurochem 106:1503-14. 2008
    ..to avoid foods and beverages with added sugars; to eat whole, unrefined foods with natural fats, especially fish, nuts and seeds, olives and olive oil; and to minimize foods that disrupt insulin and blood sugar balance...
  17. doi request reprint Personalized medicine in traumatic brain injury
    Giulio Maria Pasinetti
    Department of Neurology, Mount Sinai School of Medicine, One Gustave L Levy Place, Box 1137, New York, NY 10029, USA
    Psychiatr Clin North Am 33:905-13. 2010
    ..It is possible that the availability of TBI biomarkers may provide potential elements with clinical relevance to prevention, prognosis, and treatment of postconcussive disorders...
  18. pmc Development of a grape seed polyphenolic extract with anti-oligomeric activity as a novel treatment in progressive supranuclear palsy and other tauopathies
    Giulio Maria Pasinetti
    Center of Excellence for Novel Approaches to Neurodiagnostics and Neurotherapeutics, Brain Institute, Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029 6574, USA
    J Neurochem 114:1557-68. 2010
    ..In this mini-review article, we discuss the biochemical characterization of GSPE in our laboratory and its potential preventative and therapeutic role in model systems of abnormal tau processing pertinent to PSP and related tauopathies...
  19. ncbi request reprint Identification of potential CSF biomarkers in ALS
    G M Pasinetti
    Geriatric Research, Education, and Clinical Center, Bronx Veterans Affairs Medical Center, Bronx, NY, USA
    Neurology 66:1218-22. 2006
    ..The clinical diagnosis of ALS is based entirely on clinical features. Identification of biomarkers for ALS would be important for diagnosis and might also provide clues to pathogenesis...
  20. pmc Preclinical study of dimebon on β-amyloid-mediated neuropathology in Alzheimer's disease
    Jun Wang
    Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029 USA
    Mol Neurodegener 6:7. 2011
    ..Proper interpretations of these clinical observations, as well as future development of dimebon in AD treatment are complicated by the lack of concrete information on the mechanisms by which dimebon might benefit AD...
  21. pmc Peroxisome proliferator activator receptor gamma coactivator-1alpha (PGC-1α) improves motor performance and survival in a mouse model of amyotrophic lateral sclerosis
    Wei Zhao
    Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Mol Neurodegener 6:51. 2011
    ..abstract:..
  22. doi request reprint Neuroprotective and metabolic effects of resveratrol: therapeutic implications for Huntington's disease and other neurodegenerative disorders
    Giulio Maria Pasinetti
    Center of Excellence for Research in Complementary and Alternative Medicine in Alzheimer s Disease, Department of Neurology, Mount Sinai School of Medicine, 1498 Madison Avenue, New York, NY 10029, USA
    Exp Neurol 232:1-6. 2011
    ..study and discusses the further prospects of resveratrol and other polyphenols, including novel grape-derived polyphenols, in the treatment of HD and other neurodegenerative disorders...
  23. ncbi request reprint Cyclo-oxygenase inhibitors and Alzheimer's: are we well ADAPTed?
    Giulio Maria Pasinetti
    Neuroinflammation Research Laboratories, Department of Psychiatry, The Mount Sinai School of Medicine, New York, NY 10029, USA
    Lancet Neurol 1:403-4. 2002
  24. ncbi request reprint Cyclooxygenase as a target for the antiamyloidogenic activities of nonsteroidal anti-inflammatory drugs in Alzheimer's disease
    Giulio Maria Pasinetti
    Neuroinflammation Research Laboratories, Department of Psychiatry, School of Medicine, Mount Sinai Medical Center, One Gustave L Levy Place, New York, N Y 10029, USA
    Neurosignals 11:293-7. 2002
    ....
  25. ncbi request reprint Moderate consumption of Cabernet Sauvignon attenuates Abeta neuropathology in a mouse model of Alzheimer's disease
    Jun Wang
    Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L Levy Pl, New York, NY 10029, USA
    FASEB J 20:2313-20. 2006
    ....
  26. ncbi request reprint Connective tissue growth factor (CTGF) expression in the brain is a downstream effector of insulin resistance- associated promotion of Alzheimer's disease beta-amyloid neuropathology
    Zhong Zhao
    Neuroinflammation Research Laboratories, Mount Sinai School of Medicine, New York, NY 10029, USA
    FASEB J 19:2081-2. 2005
    ....
  27. ncbi request reprint Amyloid immunization in Alzheimer's disease: do we promote amyloid scavenging at the cost of inflammatory degeneration?
    Giulio Maria Pasinetti
    Department of Psychiatry, Neuroinflammation Research Laboratories, Mount Sinai School of Medicine, New York, NY 10089, USA
    Neurobiol Aging 23:665-6. 2002
  28. pmc Heterogeneity in red wine polyphenolic contents differentially influences Alzheimer's disease-type neuropathology and cognitive deterioration
    Lap Ho
    Department of Psychiatry, Mount Sinai School of Medicine, NY, USA
    J Alzheimers Dis 16:59-72. 2009
    ..Results from these studies suggest the possibility of developing a "combination" of dietary polyphenolic compounds for AD prevention and/or therapy by modulating multiple Abeta-related mechanisms...
  29. pmc Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease
    Jun Wang
    Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Clin Invest 117:3393-402. 2007
    ..These preclinical studies suggest that certain antihypertensive drugs may have AD-modifying activity and may protect against progressive Abeta-related memory deficits in subjects with AD or in those at high risk of developing AD...
  30. ncbi request reprint Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease
    Lap Ho
    Neuroinflammation Research Laboratories, Department of Psychiatry, Mount Sinai School of Medicine, New York, New York, USA
    FASEB J 18:902-4. 2004
    ....
  31. ncbi request reprint Caloric intake and Alzheimer's disease. Experimental approaches and therapeutic implications
    Giulio Maria Pasinetti
    Neuroinflammation Research Laboratories, Department of Psychiatry, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY 10029, USA
    Interdiscip Top Gerontol 35:159-75. 2007
    ....
  32. ncbi request reprint Cyclooxygenase (COX)-2 and cell cycle activity in a transgenic mouse model of Alzheimer's disease neuropathology
    Zhongmin Xiang
    Neuroinflammation Research Laboratories, Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Neurobiol Aging 23:327-34. 2002
    ....
  33. ncbi request reprint Caloric restriction attenuates beta-amyloid neuropathology in a mouse model of Alzheimer's disease
    Jun Wang
    Neuroinflammation Research Laboratories, Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029, USA
    FASEB J 19:659-61. 2005
    ....
  34. pmc Grape seed polyphenolic extract as a potential novel therapeutic agent in tauopathies
    Lap Ho
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Alzheimers Dis 16:433-9. 2009
    ....
  35. ncbi request reprint Increased neuronal injury in transgenic mice with neuronal overexpression of human cyclooxygenase-2 is reversed by hypothermia and rofecoxib treatment
    Zhongmin Xiang
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Curr Neurovasc Res 4:274-9. 2007
    ....
  36. ncbi request reprint Role of cyclooxygenase-2 in neuronal cell cycle activity and glutamate-mediated excitotoxicity
    Mana Mirjany
    Neuroinflammation Research Laboratories of the Department of Psychiatry, The Mount Sinai School of Medicine, New York, New York 10029, USA
    J Pharmacol Exp Ther 301:494-500. 2002
    ..These data indicate that hCOX-2 overexpression causes neuronal cell cycle deregulation in the brain and provides further rationale for targeting neuronal COX-2 in neuroprotective therapeutic research...
  37. pmc Regulation of forkhead transcription factor FoxO3a contributes to calorie restriction-induced prevention of Alzheimer's disease-type amyloid neuropathology and spatial memory deterioration
    Weiping Qin
    Department of Psychiatry, Mount Sinnai School of Medicine, New York, NY 10029, USA
    Ann N Y Acad Sci 1147:335-47. 2008
    ..This study provides a novel metabolic pathway for prevention and/or treatment of AD...
  38. ncbi request reprint From epidemiology to therapeutic trials with anti-inflammatory drugs in Alzheimer's disease: the role of NSAIDs and cyclooxygenase in beta-amyloidosis and clinical dementia
    Giulio Maria Pasinetti
    Mount Sinai School of Medicine, Department of Psychiatry, New York, USA
    J Alzheimers Dis 4:435-45. 2002
    ..These discussions may provide important criterion for the design of clinical trials of anti-inflammatory drugs in AD...
  39. ncbi request reprint Cyclooxygenase-2 promotes amyloid plaque deposition in a mouse model of Alzheimer's disease neuropathology
    Zhongmin Xiang
    Neuroinflammation Research Laboratories, Department of Psychiatry, and Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Gene Expr 10:271-8. 2002
    ..Collectively these data suggest that COX-2 influences APP processing and promotes amyloidosis in the brain...
  40. ncbi request reprint Cyclooxygenase (COX)-2 and COX-1 potentiate beta-amyloid peptide generation through mechanisms that involve gamma-secretase activity
    Weiping Qin
    Neuroinflammation Research Laboratories, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Biol Chem 278:50970-7. 2003
    ....
  41. ncbi request reprint Calorie restriction attenuates Alzheimer's disease type brain amyloidosis in Squirrel monkeys (Saimiri sciureus)
    Weiping Qin
    Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    J Alzheimers Dis 10:417-22. 2006
    ..Collectively, the study suggests that investigation of the role of CR in non-human primates may provide a valuable approach for further clarifying the role of CR in AD...
  42. ncbi request reprint Induction of the complement component C1qB in brain of transgenic mice with neuronal overexpression of human cyclooxygenase-2
    Lauren Spielman
    Neuroinflammation Research Laboratories, Department of Psychiatry, Box 1229, Mount Sinai School of Medicine, 1 Gustave L Levy Place, New York, NY 10029, USA
    Acta Neuropathol 103:157-62. 2002
    ..Because there is extensive evidence that C1q and other complement components are involved in Alzheimer's disease (AD) neurodegeneration, this study advances our understanding of the apparent benefits of COX-2 inhibition in AD...
  43. ncbi request reprint Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease
    Zhong Zhao
    Neuroinflammation Research Laboratories, The Mount Sinai School of Medicine, New York, NY 10029, United States
    Neurobiol Aging 28:824-30. 2007
    ....
  44. ncbi request reprint Expression of tau reduces secretion of Abeta without altering the amyloid precursor protein content in CHOsw cells
    Zhong Zhao
    Neuroinflammation Research Laboratories, Department of Psychiatry of the Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    FEBS Lett 579:2119-24. 2005
    ..This was accompanied by a reduction in the gamma-secretase and an increase in the insulin degrading enzyme activities. Our results suggest that tau may play an inhibitory role in the amyloidogenic activity of APP...
  45. ncbi request reprint The role of Sirt1: at the crossroad between promotion of longevity and protection against Alzheimer's disease neuropathology
    Jun Wang
    Center of Excellence for Novel Approaches to Neurodiagnostics and Neurotherapeutics, Brain Institute, Center of Excellence for Research in Complementary and Alternative Medicine in Alzheimer s Disease, Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Biochim Biophys Acta 1804:1690-4. 2010
    ..We will discuss Sirt1 as a potential novel target, in addition to the development of Sirt1 activators for the prevention and treatment of Alzheimer's disease...
  46. doi request reprint Carvedilol reestablishes long-term potentiation in a mouse model of Alzheimer's disease
    Isabel Arrieta-Cruz
    Department of Neurology, Mount Sinai School of Medicine, New York, New York 10029, USA
    J Alzheimers Dis 21:649-54. 2010
    ..These results suggest that carvedilol reestablishes basal synaptic transmission, enhances neuronal plasticity and suppresses neuronal hyperexcitability in TgCRND8 mice...
  47. ncbi request reprint Polyphenolic compounds for treating neurodegenerative disorders involving protein misfolding
    Lap Ho
    Center of Excellence for Novel Approaches to Neurodiagnostics and Neurotherapeutics, Brain Institute, Center of Excellence for Research in Complementary and Alternative Medicine in Alzheimer s Disease, Department of Neurology, Mount Sinai School of Medicine, New York, NY 10029, USA
    Expert Rev Proteomics 7:579-89. 2010
    ..Collectively, available information supports continued development of the GSPE for treating a variety of neurodegenerative disorders involving misfolded protein-mediated neuropathologic mechanisms...
  48. ncbi request reprint Caspase gene expression in the brain as a function of the clinical progression of Alzheimer disease
    Patrick N Pompl
    Neuroinflammation Research Laboratories, Department of Psychiatry, Mount Sinai School of Medicine, One Gustave L Levy Place, New York, NY 10029, USA
    Arch Neurol 60:369-76. 2003
    ..Caspase gene expression has previously been reported in terminal Alzheimer disease (AD) brain, but, currently, little is known about the temporal pattern of caspase gene expression relative to the onset and clinical progression of AD...
  49. pmc Alzheimer's disease biomarker discovery in symptomatic and asymptomatic patients: experimental approaches and future clinical applications
    Lap Ho
    Center of Excellence for Novel Approaches to Neurodiagnostics and Neurotherapeutics, Brain Institute, and Center of Excellence in Complementary and Alternative Medicine in Alzheimer s Disease, Department of Neurology, Mount Sinai School of Medicine, 1 Gustave L Levy Place, Box 1137, New York, NY 10029, USA
    Exp Gerontol 45:15-22. 2010
    ..The availability of biomarkers that promote early disease diagnosis, particularly among asymptomatic patients, will lead to the application of personalized medicine in AD...
  50. ncbi request reprint From proteomics to biomarker discovery in Alzheimer's disease
    Lap Ho
    Neuroinflammation Research Laboratories of the Department of Psychiatry, Mount Sinai School of Medicine, New York, NY 10029, USA
    Brain Res Brain Res Rev 48:360-9. 2005
    ....
  51. ncbi request reprint Immunomodulation with glatiramer acetate prevents long-term inflammatory pain
    Naresh Sharma
    Department of Psychiatry, Mount Sinai School of Medicine, New York, New York 10029, USA
    Int J Neurosci 118:433-53. 2008
    ..This study is consistent with the hypothesis that a novel mechanism through which GA immunization therapy may beneficially influence long-term allodynia and hyperalgesia is through central regulation of fractalkine-mediated responses...
  52. ncbi request reprint Amyloid beta-peptide and amyloid pathology are central to the oxidative stress and inflammatory cascades under which Alzheimer's disease brain exists
    D Allan Butterfield
    Department of Chemistry, Center of Membrane Sciences, University of Kentucky, Lexington, KY 40506 0055, USA
    J Alzheimers Dis 4:193-201. 2002
    ..This review briefly examines each of these sources of oxidative stress and inflammation in AD brain and discusses their potential roles in the clinical progression of AD dementia...

Research Grants20

  1. A modified dietary regiment as a potential novel therapeutic intervention in ALS.
    Giulio Pasinetti; Fiscal Year: 2007
    ....
  2. Protective roles of grape-derived polyphenols in Alzheimer's disease
    Giulio Pasinetti; Fiscal Year: 2007
    ..We are confident that the information that will come from this work will have a major impact on protective roles of grapederived polyphenols in Alzheimer's disease. ..
  3. COMPLEMENT AND NEUROPROTECTION: ALZHEIMER'S DISEASE
    Giulio Pasinetti; Fiscal Year: 2002
    ..Further characterization of the complex role of complement proteins in neurodegeneration is essential especially in view of the possibility that the complement system represents a target for therapeutic interventions in AD. ..
  4. Cell Cycle and COX-2 in a Mouse Model of Alzheimer's
    Giulio Pasinetti; Fiscal Year: 2002
    ....
  5. Cell Cycle and COX-2 in a Mouse Model of Alzheimer's
    Giulio Pasinetti; Fiscal Year: 2003
    ....
  6. Cell Cycle and COX-2 in a Mouse Model of Alzheimer's
    Giulio Pasinetti; Fiscal Year: 2004
    ....
  7. Pinitol a Natural Extract from Pine Cones and Alzheimer's Disease
    Giulio Pasinetti; Fiscal Year: 2006
    ..abstract_text> ..
  8. Anti-hypertensive drugs that prevent Alzheimer's disease beta-amyloid pathology a
    Giulio Pasinetti; Fiscal Year: 2007
    ....
  9. Cell Cycle and COX-2 in a Mouse Model of Alzheimer's
    Giulio Pasinetti; Fiscal Year: 2001
    ....
  10. CYCLOOXYGENASE AND ANTI-INFLAMMATORY DRUGS IN AD
    Giulio Pasinetti; Fiscal Year: 2001
    ..The outcome of the proposed studies will be immediately relevant to the design of human trials. ..
  11. CYCLOOXYGENASE AND ANTI-INFLAMMATORY DRUGS IN AD
    Giulio Pasinetti; Fiscal Year: 1999
    ..The outcome of the proposed studies will be immediately relevant to the design of human trials. ..
  12. CYCLOOXYGENASE IN NEURODEGENERATION
    Giulio Pasinetti; Fiscal Year: 1999
    ..Aim 4. To study the role of COX-2 overexpression in bigenic NHC X APPsw (Hsiao mice) which are hypothesized to have accelerated neurodegeneration and cognitive impairment. ..
  13. COMPLEMENT AND NEUROPROTECTION: ALZHEIMER'S DISEASE
    Giulio Pasinetti; Fiscal Year: 2000
    ..Further characterization of the complex role of complement proteins in neurodegeneration is essential especially in view of the possibility that the complement system represents a target for therapeutic interventions in AD. ..
  14. CYCLOOXYGENASE AND ANTI-INFLAMMATORY DRUGS IN AD
    Giulio Pasinetti; Fiscal Year: 2000
    ..The outcome of the proposed studies will be immediately relevant to the design of human trials. ..
  15. CYCLOOXYGENASE IN NEURODEGENERATION
    Giulio Pasinetti; Fiscal Year: 2000
    ..Aim 4. To study the role of COX-2 overexpression in bigenic NHC X APPsw (Hsiao mice) which are hypothesized to have accelerated neurodegeneration and cognitive impairment. ..
  16. COMPLEMENT AND NEUROPROTECTION: ALZHEIMER'S DISEASE
    Giulio Pasinetti; Fiscal Year: 2001
    ..Further characterization of the complex role of complement proteins in neurodegeneration is essential especially in view of the possibility that the complement system represents a target for therapeutic interventions in AD. ..